Recent advances in T-cell immunotherapy for haematological malignancies

Rayne H. Rouce, Sandhya Sharma, Mai Huynh, Helen Heslop

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


In vitro discoveries have paved the way for bench-to-bedside translation in adoptive T cell immunotherapy, resulting in remarkable clinical responses in a variety of haematological malignancies. Adoptively transferred T cells genetically modified to express CD19 CARs have shown great promise, although many unanswered questions regarding how to optimize T-cell therapies for both safety and efficacy remain. Similarly, T cells that recognize viral or tumour antigens though their native receptors have produced encouraging clinical responses. Honing manufacturing processes will increase the availability of T-cell products, while combining T-cell therapies has the ability to increase complete response rates. Lastly, innovative mechanisms to control these therapies may improve safety profiles while genome editing offers the prospect of modulating T-cell function. This review will focus on recent advances in T-cell immunotherapy, highlighting both clinical and pre-clinical advances, as well as exploring what the future holds.

Original languageEnglish (US)
Pages (from-to)688-704
Number of pages17
JournalBritish Journal of Haematology
Issue number5
StatePublished - Mar 1 2017


  • T cells
  • immunotherapy
  • lymphoma

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Recent advances in T-cell immunotherapy for haematological malignancies'. Together they form a unique fingerprint.

Cite this